Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious complications.
OBJECTIVE
Systemic lupus erythematosus (SLE) is the most common secondary glomerulonephritis resulting in end-stage renal disease (ESRD) among young adults in Taiwan. Studies of the infectious complications and outcomes among such SLE patients undergoing peritoneal dialysis (PD) are limited.


METHODS
A retrospective age- and gender-matched case control study.


METHODS
A university teaching hospital.


METHODS
There were 23 SLE patients with ESRD receiving PD for more than 3 months during the past 15 years. Another 46 age- and gender-matched non-SLE nondiabetic patients receiving PD were selected as the control group in this study.


METHODS
All patients underwent PD as renal replacement therapy and were regularly followed up at this hospital.


METHODS
Technique survival and incidences of exit-site infection (ESI) and peritonitis in these patients.


RESULTS
The SLE patients had a lower predialysis serum albumin than the control group (3.16 +/- 0.50 g/dL vs 3.52 +/- 0.50 g/dL, p < 0.01). The incidences of exit-site infection (ESI) and peritonitis were higher for SLE patients than for control patients (p < 0.01 and p < 0.001, respectively). Kaplan-Meier survival analysis indicated that SLE patients had shorter time intervals to first infectious complications, and poorer technique survival. Infection was the major cause of dropout and mortality in the SLE patients. The SLE patients had a reduced chance of receiving a renal transplant. The use of steroids by SLE patients was associated with a higher incidence of peritonitis (p = 0.04), but association with ESI was insignificant. In a Cox regression model, the underlying SLE was the only risk factor for technique failure and time interval to first infectious complication.


CONCLUSIONS
SLE patients undergoing PD are more susceptible to infection than age- and gender-matched non-SLE nondiabetic patients and have poorer technique survival. Systemic lupus erythematosus itself may further compromise the immunity of uremic patients.
Huang
J W
JW
Department of Internal Medicine, Far Eastern Memorial Hospital and National Taiwan University Hospital, Taipei, Republic of China.
Hung
K Y
KY
Yen
C J
CJ
Wu
K D
KD
Tsai
T J
TJ
D000328:Adult; D002408:Catheters, Indwelling / Q000009:adverse effects; D005260:Female; D006801:Humans; D007239:Infections / Q000209:etiology* / Q000382:microbiology; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008181:Lupus Nephritis / Q000401:mortality / Q000628:therapy*; D008297:Male; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000209:etiology* / Q000382:microbiology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome